Literature DB >> 18628088

Evaluation of the use of monoclonal antibodies and nested PCR for noninvasive prenatal diagnosis of hemoglobinopathies in India.

Edna D'Souza1, Pratibha M Sawant, Anita H Nadkarni, Ajit Gorakshakar, Dipika Mohanty, Kanjaksha Ghosh, Roshan B Colah.   

Abstract

Our purpose was to develop and evaluate isolation and enrichment of fetal erythroblasts and a nested polymerase chain reaction (PCR) approach using fetal erythroblasts for detecting the beta-globin gene mutations for a noninvasive prenatal diagnosis of hemoglobinopathies. Maternal blood at different periods of gestation was layered on a Percoll density gradient for enrichment of fetal nucleated RBCs (NRBCs). A combination of 3 monoclonal antibodies (CD45-peridinin chlorophyll protein, glycophorin A-phycoerythrin, and anti-hemoglobin F-fluorescein isothiocyanate) was used for flow cytometric sorting of fetal NRBCs from enriched cells. Different nested PCR-based approaches were used for identification of fetal mutations. Owing to heterogeneity of beta-thalassemia mutations in the population of India, we had to screen for 12 mutations and were able to give an accurate diagnosis in 84 (84.0%) of 100 cases when compared with chorionic villus sampling or cordocentesis and DNA analysis.This nested PCR approach enabled amplification of small quantities of DNA from fetal erythroblasts, providing a cost-effective method for noninvasive diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628088     DOI: 10.1309/1WDCPGTAJJ6A938V

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Rapid Flow cytometric prenatal diagnosis of primary immunodeficiency (PID) disorders.

Authors:  Anju Mishra; Maya Gupta; Aparna Dalvi; Kanjaksha Ghosh; Manisha Madkaikar
Journal:  J Clin Immunol       Date:  2014-02-18       Impact factor: 8.317

Review 2.  Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India.

Authors:  R B Colah; A C Gorakshakar; A H Nadkarni
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.